Search results for Cdk4/6 Inhibitor

<![CDATA[FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhi...

Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study

A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second submission for a molecule already under review by the FDA.

EMA Recommends Generic for Advanced/Metastatic Breast Cancer

By: Sophie Cousins From: medscape.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Pa...

New Treatment, Dato-DXd, Improves Survival for Aggressive Breast Cancer

THURSDAY, April 23, 2026 — Triple-negative breast cancer (TNBC) has long been considered one of the most difficult types to fight. It is aggressive, often strikes women under age...

AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer

Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of...

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with pers...

Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines

Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership...

Bristol Myers unveils data for one of its next-gen blood cancer drugs

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical...

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Revolution drug shows promise in early pancreatic cancer

The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.

Pumitamig Plus Chemo Drives Strong Responses Across PD-L1 Subgroups of Metastatic TNBC

By: Ashling Wahner From: onclive.com The VEGF/PD-L1–directed bispecific antibody pumitamig (BNT327/BMS986545) has been shown to restore immune activity and improve outcomes in pati...

Oral Paclitaxel DHP107 Non-inferior to IV for Metastatic Breast Cancer

From: oncnursingnews.com Patients with HER2-negative metastatic breast cancer may soon have a more convenient treatment option, as the phase 3 OPTIMAL trial (NCT03315364) confirms...

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSI...

HONG KONG, April 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating ca...

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug Daraxonrasib

May 01, 2026 -- Today, the U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an ex...

AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative m...

Merck ADC, licensed from China, hits mark in first big global trial

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next deca...

Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer

By: Mary Ellen Schneider From: cancertherapyadvisor.com Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-posit...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...